{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:01:15Z","timestamp":1776060075258,"version":"3.50.1"},"reference-count":30,"publisher":"Korean Cancer Association","issue":"2","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100007033","name":"Eisai Korea Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007033","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Seagen"},{"name":"MSD"},{"name":"Roche"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Novartis"},{"name":"AstraZeneca"},{"name":"Lilly"},{"name":"GSK"},{"name":"Boehringer Ingelheim"},{"name":"Sanof"},{"name":"Daiichi-Sankyo"},{"name":"Qurient"},{"name":"Dragonfly"},{"name":"Eikon"},{"name":"Gilead"},{"name":"Celcuity"},{"name":"Bristol Myers Squibb"},{"name":"HLB Life Science"},{"name":"Sermonix Pharmaceuticals"},{"name":"Olema"},{"name":"Hanmi Pharm"},{"name":"Ildong Pharmaceutical"},{"name":"Samyang Holdings"}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2026,4,15]]},"abstract":"<jats:p>PurposeThis 6-year post-marketing surveillance (PMS) study was conducted in South Korea to evaluate the real-world safety and effectiveness of eribulin in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.Materials and MethodsDuring the study period (17 August 2012 to 16 August 2018), case-report files (CRFs) of patients receiving eribulin were collected. The main study endpoint was to assess the safety of eribulin. Evaluation of the effectiveness of eribulin was an exploratory endpoint. Patients were followed for 1 year after eribulin initiation.ResultsCRFs were collected from 64 investigators at 64 sites for 1,079 patients. The safety analysis set (SAS) included 1,001 eribulin recipients; effectiveness was assessed in 244 patients. In the SAS, patients were predominantly female (99.6%), with a median age of 53.0 years, and diagnosed with metastatic breast cancer (92.0%). Eribulin was administered as a median 4th line chemotherapy. A total of 2,124 treatment-emergent adverse events (TEAEs) were reported in 661 patients (66.0%). Neutropenia was the most common TEAE (32.5% of patients), occurring at a median of 9-11 days from initial eribulin administration. Overall response and disease control rates were 31.7% and 95.6%, respectively, and the median duration of eribulin use (time to treatment failure) was 3.0 months.ConclusionThis large real-world PMS analysis in patients with advanced or metastatic breast cancer demonstrated the effectiveness of eribulin and found no new safety concerns relative to safety information from prior clinical and real-world studies, and approvals in South Korea and other countries.<\/jats:p>","DOI":"10.4143\/crt.2024.1142","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:25:21Z","timestamp":1745814321000},"page":"513-524","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Eribulin in Patients with Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes in Real-World Clinical Practice: A 6-Year Post-marketing Surveillance Study in South Korea"],"prefix":"10.4143","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4420-4035","authenticated-orcid":true,"given":"Yee Soo","family":"Chae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung A","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Sun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Jin","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keon Uk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngji","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-7224","authenticated-orcid":true,"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"ref2","volume-title":"WHO launches new roadmap on breast cancer [Internet]","year":"2023"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.128"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00227"},{"key":"ref5","first-page":"6","volume-title":"Chemotherapy treatment considerations in metastatic breast cancer","author":"Hanna","year":"2021"},{"key":"ref6","first-page":"1013","volume-title":"In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","author":"Towle","year":"2001"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-3252"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.08.008"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-10-1874"},{"key":"ref10","first-page":"914","volume-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","author":"Cortes","year":"2011"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.52.4892"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3144-y"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.02.002"},{"key":"ref14","volume-title":"MedDRA: Medical Dictionary for Regulatory Activities [Internet]","year":"2023"},{"key":"ref15","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) [Internet]","year":"2024"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz090"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-09-0344"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyf014"},{"key":"ref19","volume-title":"Halaven (eribulin) prescribing information [Internet]","year":"2024"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2016.191"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211030210"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-04-0345"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-10-4184"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-013-9394-3"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2574-2"},{"key":"ref26","volume-title":"European Medicines Agency. Assessment report for Halaven (eribulin) [Internet]","year":"2011"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2002.00564.x"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13576"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01613-6"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6301"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-1142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.1142","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-1142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:31:49Z","timestamp":1776058309000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.1142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2024.1142","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"2024-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-28","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}